Snehal Patel Purchases 1,500 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Posted by Francis Steltz on Jul 29th, 2026

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel bought 1,500 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average price of $13.62 per share, for a total transaction of $20,430.00. Following the completion of the purchase, the chief executive officer owned 5,609,202 shares in the company, valued at $76,397,331.24. The trade was a 0.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

On Thursday, July 23rd, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $13.14 per share, for a total transaction of $32,850.00.
On Friday, July 24th, Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $12.88 per share, with a total value of $14,168.00.

Greenwich LifeSciences Price Performance

NASDAQ GLSI opened at $13.45 on Wednesday. The company has a market capitalization of $197.45 million, a PE ratio of -8.57 and a beta of 1.40. The company has a fifty day moving average of $21.63 and a 200 day moving average of $24.26. Greenwich LifeSciences, Inc. has a 1 year low of $7.78 and a 1 year high of $34.10.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GLSI. HC Wainwright lifted their price objective on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Finally, Wall Street Zen lowered shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $57.00.

View Our Latest Stock Report on GLSI

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of GLSI. Marshall Wace LLP acquired a new stake in shares of Greenwich LifeSciences during the second quarter worth about $509,000. Bank of New York Mellon Corp grew its stake in shares of Greenwich LifeSciences by 235.5% in the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after acquiring an additional 32,657 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Greenwich LifeSciences during the fourth quarter worth $605,000. Man Group plc acquired a new stake in shares of Greenwich LifeSciences in the fourth quarter valued at $590,000. Finally, Sei Investments Co. acquired a new stake in shares of Greenwich LifeSciences in the first quarter valued at $627,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.